Camall

Camall Company was a pharmaceutical manufacturer based in Washington, Michigan, that specialized in the production of generic drug products. The company was primarily known for its portfolio of abbreviated new drug applications (ANDAs) for various small molecule therapies, including the weight-loss medication phendimetrazine tartrate (marketed as Cam-Metrazine) and the diuretic hydrochlorothiazide. Historically, Camall operated as a supplier of brand-equivalent substitutes in the United States market and was involved in legal proceedings alongside other generic manufacturers like Eon Labs. In recent years, the company has become inactive, with the U.S. Food and Drug Administration (FDA) moving to withdraw approval of its remaining drug applications due to a failure to submit required annual reports. Consequently, Camall is no longer an active participant in the pharmaceutical manufacturing sector.